Skip to main content

Armata Pharmaceuticals, Inc.

ARMP
Exchange
NYSE
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000921114

No open-market purchases or sales by Armata Pharmaceuticals, Inc. insiders were filed in the last 90 days; 53 institutions reported holding it in 13F filings for Q2 2026, worth $32.3M in total; no superinvestor holds it.

Key figures

Market capClose on Nov 16, 2026
$111.2M
Insider buysOpen market, last 90 days
0
Insider sellsOpen market, last 90 days
0
13F holdersQ2 2026, +8 vs. previous quarter
53
13F valueReported value at the end of Q2 2026
$32.3M
Superinvestors holdingAt the end of Q2 2026
0

Price chart

From SEC filings, in USD.

Revenue, FY2025
–
No comparable prior period
Net income, FY2025
-$173.8M
No comparable prior period
Free cash flow, FY2025
-$26.3M
No comparable prior period
Revenue, Q3 FY2026
–
No comparable prior period

Short interest

See short data

From FINRA, settlement date Oct 30, 2026.

Short interest
912.6K
Shares sold short
Change
+13.0K
+1.4% vs. previous
Days to cover
9.78
At average daily volume

Superinvestors holding ARMP, Q2 2026

Go to the superinvestors tab

No superinvestor reported holding ARMP at the end of Q2 2026.

Latest insider trades

See all insider trades

Open-market purchases and sales by Armata Pharmaceuticals, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 12, 2023 (view filing)9:21 PM ETJan 102 daysInnoviva, Inc. and 1 otherDirector, 10% OwnerPPurchase+19.7M–––DerivativePrice outlier
Apr 1, 2022 (view filing)4:52 PM ETMar 311 dayInnoviva, Inc. and 1 otherDirector, 10% OwnerPPurchase+5.39M$5.00+$26.9M+49.0%16.4M after
Apr 1, 2022 (view filing)4:52 PM ETMar 311 dayInnoviva, Inc. and 1 otherDirector, 10% OwnerPPurchase+2.69M$0.00$0–2.69M afterDerivative
Feb 11, 2022 (view filing)6:56 PM ETFeb 92 daysInnoviva, Inc. and 1 otherDirector, 10% OwnerPPurchase+3.61M$5.00+$18.1M+49.1%11.0M after
Feb 11, 2022 (view filing)6:56 PM ETFeb 92 daysInnoviva, Inc. and 1 otherDirector, 10% OwnerPPurchase+1.81M$5.00+$9.04M–1.81M afterDerivative
Nov 1, 2021 (view filing)2:20 PM ETOct 293 daysInnoviva, Inc. and 1 otherDirector, 10% OwnerPPurchase+1.21M$3.30+$4.00M+19.7%7.37M after

Top 10 13F holders, Q2 2026

See all 53 holders

The largest institutional positions in Armata Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.

Institutions holding ARMP in Q2 2026
InstitutionSharesValue% of portfolioChange in sharesAction
Madison Asset Management, LLC2,107,175$13.7M0.16%−5000.0%Reduced
BlackRock, Inc.559,986$3.63M0.00%+494,936+760.9%Added
Vanguard Capital Management LLC487,968$3.16M0.00%+121,940+33.3%Added
Millennium Management LLC470,500$3.05M0.00%+212,508+82.4%Added
Geode Capital Management, LLC270,550$1.75M0.00%+155,995+136.2%Added
Dauntless Investment Group, LLC203,891$1.32M2.29%+113,311+125.1%Added
State Street Corp129,600$839.8K0.00%+78,800+155.1%Added
Northern Trust Corp89,791$581.8K0.00%+65,145+264.3%Added
Vanguard Portfolio Management LLC81,354$527.2K0.00%+81,354New
Edgewood Management LLC80,000$518.4K0.01%−20,000−20.0%Reduced

Holders of 5% or more of ARMP

See all 1 holders and filings

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Armata Pharmaceuticals, Inc..

Largest holders of ARMP from 13D and 13G filings
HolderLatest formStakeChangeFirst filedLatest filingFiling
Innoviva, Inc.13D/A82.70%55.5M shares−0.40 ppfrom 83.10%Jan 27, 202114 filingsMay 13, 2026SEC